Scinai Immunotherapeutics Ltd.
SCNI
$0.25
▲
+0.01
(+5.35%)
at close
9
Visible periods
20
Metrics
Peer-ranked
Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome
Analytical Summary
Scinai Immunotherapeutics Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.
Market Cap
—
Dividend Yield
—
Revenue Growth
—
Op. Margin
—
ROIC
None
FCF / Share
None
Trailing P/E
—
Price / Book
428.0x
FCF Yield
—
Debt / Equity
—
info
Valuation on last close. End-of-day price, Aug 7, 2026.
9-Year Financial Trajectory
Quarterly
Metric
Value
Trend
Year over Year
Percentile
Net Income
Profit after all expenses
$-3.52M
FCF / Share
Free cash flow per share
$-0.00
trending_up
Bullish Indicators
- No bullish signals detected.
warning
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Profitability
0
Returns
8
Cash Quality ↓
50
Financial view
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
Is growth accelerating?
3 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q1 FY2023 Mar 31, 2023 10-Q ↗ | Q4 FY2022 Dec 31, 2022 10-K ↗ | Q1 FY2022 Mar 31, 2022 10-Q ↗ | Q4 FY2021 Dec 31, 2021 10-K ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2017 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|
| EPS Growth YoY (%) | — | — | — |
0.0%
Caution
Caution
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — | — | — | — |
| Net Income Growth YoY (%) | — | — | — |
-42.0%
Weak
Weak
Year-over-year change in net income |
— | — | — | — | — |
| FCF Growth YoY (%) | — | — | — |
-8.4%
Weak
Weak
Year-over-year change in free cash flow |
— | — | — | — | — |
Are margins durable?
1 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q1 FY2023 Mar 31, 2023 10-Q ↗ | Q4 FY2022 Dec 31, 2022 10-K ↗ | Q1 FY2022 Mar 31, 2022 10-Q ↗ | Q4 FY2021 Dec 31, 2021 10-K ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2017 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|
| FCF / Net Income (x) | — | — | — |
0.87x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
0.66x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
— | — | — |
Is capital allocation efficient?
3 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q1 FY2023 Mar 31, 2023 10-Q ↗ | Q4 FY2022 Dec 31, 2022 10-K ↗ | Q1 FY2022 Mar 31, 2022 10-Q ↗ | Q4 FY2021 Dec 31, 2021 10-K ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2017 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|
| Return on Invested Capital (%) | — | — | — |
52.3%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
239.7%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — | — |
| Return on Capital (%) (%) | — | — | — |
-13.7%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — | — | — |
| Return on Common Equity (%) (%) | — | — | — |
73.1%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+387%)
|
— |
287.1%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+1814%)
|
— | — | — |
Is the balance sheet risky?
3 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q1 FY2023 Mar 31, 2023 10-Q ↗ | Q4 FY2022 Dec 31, 2022 10-K ↗ | Q1 FY2022 Mar 31, 2022 10-Q ↗ | Q4 FY2021 Dec 31, 2021 10-K ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2017 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|
| Debt to Equity (x) | — | — | — | — |
-0.22x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-136%)
|
— |
0.38x
Good
Good
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-36%)
|
— | — |
| Interest Coverage (x) | — | — | — |
-4.39x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
— | — | — | — | — |
| Net Debt (USD) | $-1.66M | $-1.96M | $-4.87M | $-10.80M | $-13.69M | $-15.39M | $-17.00M | — | — |
How resilient is the balance sheet?
2 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q1 FY2023 Mar 31, 2023 10-Q ↗ | Q4 FY2022 Dec 31, 2022 10-K ↗ | Q1 FY2022 Mar 31, 2022 10-Q ↗ | Q4 FY2021 Dec 31, 2021 10-K ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2017 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|
| Working Capital (USD) | $469.00K | $585.00K | $3.67M | $8.47M | $12.03M | — | $15.40M | — | — |
| Total Equity (USD) | $8.10M | $9.98M | $-4.57M | $-4.81M | $-1.76M | $-862.00K | $982.00K | $-15.04M | — |
What is driving earnings?
3 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q1 FY2023 Mar 31, 2023 10-Q ↗ | Q4 FY2022 Dec 31, 2022 10-K ↗ | Q1 FY2022 Mar 31, 2022 10-Q ↗ | Q4 FY2021 Dec 31, 2021 10-K ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2017 20-F ↗ |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation Expense (USD) | — | — | — | $138.00K | — | $134.00K | — | — | — |
| Net Income, GAAP (USD) | — | — | — | $-3.52M | — | $-2.48M | — | — | — |
| Operating Cash Flow (USD) | — | — | — | $-3.06M | — | $-1.10M | — | — | — |
⌨️ Keyboard Shortcuts
/ Search
Esc Clear
A Annual
Q Quarterly
1-7 Jump to category
R Reset
Secondary lens
Benchmark Lens
Compare SCNI against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare SCNI against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for SCNI
Bullish
0
No bullish signals detected
Bearish
1
Return on Common Equity (%)
-102.5%
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How SCNI compares to all companies
Return on Common Equity (%)
-102.5%
Bottom 25%
Peers: Top 78%
Peer Comparison
SCNI vs similar peers
Return on Common Equity (%)
SCNI
-102.5%
#30 of 38
ELUT
192.9%
CSBR
124.6%
CGEN
34.4%
Peer median: -44.66
Profit Margin (%)
SCNI
—
#None of 9
CGEN
48.6%
BDTX
32.0%
DTIL
10.4%
Peer median: -12.52
Debt to Equity
SCNI
—
#None of 8
CGON
0.00x
TSHA
0.20x
TCRX
0.26x
Peer median: 0.37
Operating Margin (%)
SCNI
—
#None of 9
CGEN
43.1%
BDTX
17.9%
CSBR
8.0%
Peer median: -38.08
Compare SCNI with peers
Stack SCNI against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 7 years · 9 quarters